PCS6422 and capecitabine

DRUG2 trials

Sponsors

Processa Pharmaceuticals

Conditions

Advanced CancerBreast CancerHER2-negative Breast CancerRefractory CancerTNBC - Triple-Negative Breast CancerTumor Gastric

Phase 1

A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors

CompletedNCT04861987

Processa PharmaceuticalsAdvanced Cancer, Refractory Cancer, Tumor Gastric

Start: 2021-06-18End: 2024-09-09Updated: 2024-10-10

Phase 2

A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

RecruitingNCT06568692

Processa PharmaceuticalsBreast Cancer, HER2-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer

Start: 2024-10-02End: 2026-10-31Target: 90Updated: 2025-06-19

Related Papers

Adaptive designed eniluracil + capecitabine phase 2 trial in advanced or metastatic breast cancer patients.

Journal of Clinical Oncology2025-05-28

Safety and efficacy of eniluracil + capecitabine (6422 + Cap) in phase 1b trial.

Journal of Clinical Oncology2025-05-28